QuickCool was founded in 2003 and has operations in Lund, Sweden. The company develops a new method for quick and selective cooling of the brain. It is possible to prevent brain damage in patients with cardiac arrest, stroke or head injuries by cooling the brain. The use of mild hypothermia or cooling the patient’s body temperature to 32-34°C is currently the only method, in addition to the use of a blood declotting agent, which has been proven to reduce damage to brain cells in the treatment of patients with insufficient blood circulation.
QuickCool has developed a patented technology that enables quick and easy cooling of the brain with the aid of a portable pump connected to balloon catheters. The catheters are inserted into the patient’s nostrils and a cold saline solution is circulated through the catheters, effectively lowering the patient’s brain temperature.
The investment in QuickCool will be made via a directed share issue and enables the company to continue its long-term development work and to launch clinical studies. ”It is delightful to have CapMan, with their experience and network within medical technology, as a major shareholder in the company. The investment provides QuickCool an opportunity to build up a strong R&D organisation and to execute the necessary clinical studies,” states Fredrik Lindblad, Managing Director of QuickCool.
”QuickCool has developed a highly innovative product and we have a strong belief in its large market capital in the emerging medtech field,” says Björn Nordenvall, Investment Director at CapMan.
To optimise the benefits of the cooling treatment, QuickCool will offer its product in future through the whole paramedic chain from ambulances to emergency care.
For more information, please contact:
Björn Nordenvall, Investment Director, CapMan Life Science, tel. +46 8 545 854 86 or + 46 706 391 010
Fredrik Lindblad, Managing Director, QuickCool AB, tel. +46 46 286 38 40 or +46 708 686 477